VRCA Stock News & Analysis | Latest Updates

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:VRCA) WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.

September 2, 2025Conference

VRCA News

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Verrica Pharmaceuticals Q1 Adj. EPS $(0.08) Beats $(0.10) Estimate, Sales $3.44M Beat $2.51M Estimate

Earnings Outlook For Verrica Pharmaceuticals

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

HC Wainwright & Co. Reiterates Neutral on Verrica Pharmaceuticalsto Neutral

Verrica Pharmaceuticals Reports 16.7% Sequential Growth In Q1 2025 With Over 10,000 YCANTH Dispensed Applicator Units And Expects Revenue To Align With Normalized Distributor Inventory Levels

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Verrica Pharmaceuticals Q4 2024 Adj. EPS $(0.18) Beats $(0.26) Estimate, Sales $344.000K Miss $1.041M Estimate

Needham Reiterates Hold on Verrica Pharmaceuticalsto Hold

Verrica Provides Business And Operational Update: Says Dispensed Applicator Units In Q4 Have Exceeded Complete Prior Quarter Even With Significant Cost Reductions In Sales And Operational Infrastructure, Observed Significant Reduction In Ycanth Distributo

Verrica Announces Proposed Public Offering; Terms Not Disclosed

HC Wainwright & Co. Downgrades Verrica Pharmaceuticals to Neutral

Needham Reiterates Hold on Verrica Pharmaceuticals

RBC Capital Downgrades Verrica Pharmaceuticals to Sector Perform, Lowers Price Target to $2

Verrica Pharmaceuticals Announces New Senior Leadership With Appointments Of Dr. Jayson Rieger As CEO And John Kirby As Interim CFO; Exploring Strategies To Strengthen Balance Sheet

Verrica Pharmaceuticals Q3 Adj $(0.43) Misses $(0.37) Estimate, Sales $(1.78M) Miss $4.63M Estimate

Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $16 Price Target